The lawsuits allege that the drug, which mimics the GLP-1 hormone in the body that aids in insulin secretion, causes severe side effects, including gastroparesis and pancreatic cancer
The FDA's draft guidance on obesity drug trials recommends monitoring for this in women [8]
Beyond summarizing pharmacological efficacy, we introduce a structured, clinically oriented psychological framework designed to guide clinical decision-making and inform future translational research, linking neurobehavioral science with routine obesity care and emphasizing personalization, early identification of relapse indicators, and the integration of psychological and pharmacological interventions
Higher doses often yield stronger efficacy but also greater gastrointestinal issues, tolerability drop-outs, etc
Some people are naturally more sensitive to GLP-1 receptor agonism, experiencing stronger appetite suppression but also more intense gastrointestinal effects
GLP-1 agonists are medications designed to replicate the effects of a natural hormone in the body called glucagon-like peptide-1
